Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes

Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes

Aims and methods: The aim of this monocentric retrospective observational study was to evaluate the 18-month safety and effectiveness of GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) 1.5 mg/once weekly as an add-on to metformin (MET) or MET plus conventional insulin secretagogues in a study coh...

Full description

Bibliographic Details
Main Authors: Maria Mirabelli, Eusebio Chiefari, Vera Tocci, Patrizia Caroleo, Stefania Giuliano, Emanuela Greco, Raul Miguel Luque, Luigi Puccio, Daniela Patrizia Foti, Antonio Aversa, Antonio Brunetti
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Journal of Clinical Medicine
Subjects:
GLP-1 receptor agonist (GLP-1 RA)
dulaglutide
liraglutide
add-on therapy
type 2 diabetes
obesity
Online Access:https://www.mdpi.com/2077-0383/10/5/985

Internet

https://www.mdpi.com/2077-0383/10/5/985

Similar Items